T-Mobile’s and the joint venture’s objectives, expectations and intentions, and the accounting treatment of the proposed transaction. There are several factors which could cause actual plans ...

U.S. sales of the treatment ... accounting for 47 percent of the global market. SK Biopharm stated that the two companies have secured the funding to develop and operate the joint venture for ...

(SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture ... epilepsy treatment is expected to grow to US$1.8 billion by 2032, with North America accounting for some ...